Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;36(2):481-494.
doi: 10.1016/j.idc.2022.01.008. Epub 2022 Jan 31.

COVID-19 Vaccines

William O Hahn  1 , Zanthia Wiley  2
Affiliations
Review

COVID-19 Vaccines

William O Hahn et al. Infect Dis Clin North Am. 2022 Jun.

Abstract

This article is a narrative review of the rapidly moving coronavirus disease 2019 vaccine field with an emphasis on clinical efficacy established in both randomized trials and postmarketing surveillance of clinically available vaccines. We review the major clinical trials that supported authorization for general use of the Janssen (Ad.26.CoV2), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines and the publicly available postmarketing information with the goal of providing a broad, clinically relevant comparison of efficacy and safety. This review is primarily focused on the US market.

Keywords: COVID-19; Janssen (Ad.26.CoV2); SARS-CoV-2; Vaccine; mRNA vaccine; post-marketing vaccine surveillance; vaccine efficacy trials.

PubMed Disclaimer

References

    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. - PMC - PubMed
    1. Sadoff J., Gray G., Vandebosch A., et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. - PMC - PubMed
    1. Falsey A.R., Sobieszczyk M.E., Hirsch I., et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 doi: 10.1056/NEJMoa2105290. - DOI - PMC - PubMed
    1. Heath P.T., Galiza E.P., Baxter D.N., et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–1183. - PMC - PubMed